<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="UTF-8">
<title>$30M Revenue Rocket, Super Spiders, and Biotech Patent Blitz Launch Morning Momentum</title>
<style>
body { font-family: Arial, Helvetica, sans-serif; background:#0f1115; color:#e6e6e6; margin:0; padding:40px; }
.container { max-width:700px; margin:auto; background:#161a21; border-radius:10px; padding:32px; box-shadow:0 0 30px rgba(0,0,0,0.4); }
h1 { margin-top:0; color:#4da3ff; }
table { width:100%; margin-top:12px; border-collapse:collapse; }
th, td { text-align:left; padding:6px 8px; border-bottom:1px solid #2a2f3a; }
ul { margin-top:12px; padding-left:20px; }
.section { margin-top:24px; }
.small { margin-top:12px; font-size:13px; color:#999; }
a { color:#4da3ff; }
</style>
</head>
<body>
  <div class="container">
    <h1>$30M Revenue Rocket, Super Spiders, and Biotech Patent Blitz Launch Morning Momentum</h1>

    <table>
      <tr><th>Ticker</th><td>TRNR</td></tr>
      <tr><th>Float</th><td>5.2 M</td></tr>
      <tr><th>IO</th><td>1.22%</td></tr>
      <tr><th>MC</th><td>2.7 M</td></tr>
      <tr><th>Extra Info</th><td>None</td></tr>
    </table>

    <div class="section">
      <strong>Summary</strong>
      <p>Press release summarizing market-moving small- and mid-cap developments: Interactive Strength (TRNR) agreed to acquire Ergatta, raising TRNR's 2026 pro forma revenue guidance by ~50% to >$30M; Ergatta is expected to generate >$10M in 2026 revenue with ~30% EBITDA margins, and the deal has a performance-linked EV cap of $19.5M (50% tied to 2026 EBITDA of ~$4M) with closing targeted for Q1 2026. Kraig Biocraft Laboratories (KBLB) activated the first wave of its 2026 production program, moving biomaterials to incubation and commencing a March production run as part of a multi-ton recombinant spider silk scale-up. Theriva Biologics (TOVX) out-licensed SYN-020 to Rasayana Therapeutics for GI/metabolic/inflammatory indications for $300K upfront, up to $38M in milestones and tiered single-digit royalties; Rasayana assumes development and commercialization costs. NorthStrive Biosciences (a PMGC/ELAB subsidiary) filed 10 U.S. patent applications expanding EL-22/EL-32 technologies into animal health and agriculture. The release is a paid editorial from 24/7 Market News, which discloses holding KBLB shares and receiving compensation.</p>
    </div>

    <div class="section">
      <strong>Positives</strong>
      <ul><li>TRNR acquisition of Ergatta raises 2026 pro forma revenue guidance to >$30M and is expected to be immediately accretive</li><li>Ergatta expected to contribute >$10M revenue in 2026 with ~30% EBITDA margins and a performance-linked EV structure (max $19.5M)</li><li>KBLB initiated first wave of 2026 production program and multi-ton scale-up for recombinant spider silk, moving toward commercial volumes</li><li>TOVX received $300K upfront from out-license and is eligible for up to $38M in milestones plus tiered single-digit royalties; licensee assumes costs</li><li>NorthStrive/ELAB filed 10 new U.S. patent applications expanding technologies into animal health and agriculture</li></ul>
    </div>

    <div class="section">
      <strong>Negatives</strong>
      <ul><li>This is a paid editorial communication from 24/7 Market News; 24/7 discloses owning KBLB shares and having been compensated</li><li>Release contains forward-looking statements and explicit risk disclaimers that actual results may differ</li><li>KBLB is an OTCQB-listed micro-/small-cap company (heightened execution and liquidity risk)</li></ul>
    </div>

    <div class="section">
      <a href="https://news.nuntiobot.com/article/1e4b005d-a156-4514-b174-e91b9f9afc77" target="_blank">Original Article</a>
    </div>

    <div class="small">TRNR â€¢ TradersLink AI News</div>
  </div>
</body>
</html>